Pre‐eclampsia and fetal growth restriction (FGR) continue to cause unacceptably high levels
of morbidity and mortality, despite significant pharmaceutical and technological advances in …

Introduction Preeclampsia and fetal growth restriction are common pregnancy complications
that significantly impact perinatal health and offspring development later in life. The origin of …

Pre-eclampsia is responsible for~ 70 000 maternal and 500 000 fetal deaths annually. The
placenta releases excess anti-angiogenic factors into the maternal circulation, causing …

The placenta is a transient organ that forms during pregnancy and acts as a biological
barrier, mediating exchange between maternal and fetal circulation. Placental disorders …

A major challenge to treating diseases during pregnancy is that small molecule therapeutics
are transported through the placenta and incur toxicities to the developing fetus. The …

The transitory placenta develops during pregnancy and mediates the blood flow between
the mother and the developing baby. Placental dysfunction, including but not limited to …

Pre-existing conditions at reproductive age, and complications arising during pregnancy can
be detrimental to maternal and fetal health. Current therapies to combat obstetric disorders …

Highlights•Preeclampsia is a serious pregnancy disorder, no curative treatment is available
yet.•Therapies aiming at regulating sFlt-1 and PlGF levels are promising approaches.• …

Preeclampsia is a complex disease affecting 2–8% of pregnancies worldwide. It poses
significant risk of maternal and perinatal morbidity and mortality. Despite the rising research …

A major challenge in developing potential treatments for pregnancy complications is
minimizing adverse effects to the fetus and mother. Placenta-targeted drug delivery could …